Nikolaus Marx

Summary

Affiliation: University of Ulm
Country: Germany

Publications

  1. ncbi C-peptide induces chemotaxis of human CD4-positive cells: involvement of pertussis toxin-sensitive G-proteins and phosphoinositide 3-kinase
    Daniel Walcher
    Department of Internal Medicine II-Cardiology, University of Ulm, Germany
    Diabetes 53:1664-70. 2004
  2. ncbi PPARalpha activators inhibit tissue factor expression and activity in human monocytes
    N Marx
    Department of Internal Medicine II Cardiology, University of Ulm, Germany
    Circulation 103:213-9. 2001
  3. ncbi Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells
    Nikolaus Marx
    Department of Internal Medicine II Cardiology, University of Ulm, Robert Koch Str 8, D 89081 Ulm, Germany
    Circ Res 94:1168-78. 2004
  4. ncbi C-peptide colocalizes with macrophages in early arteriosclerotic lesions of diabetic subjects and induces monocyte chemotaxis in vitro
    Nikolaus Marx
    Department of Internal Medicine II Cardiology, University of Ulm, Robert Koch Str 8, D 89081 Ulm, Germany
    Arterioscler Thromb Vasc Biol 24:540-5. 2004
  5. ncbi Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease
    Nikolaus Marx
    Department of Internal Medicine II Cardiology, University of Freiburg, Germany
    Circulation 107:1954-7. 2003
  6. ncbi Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease
    Nikolaus Marx
    Department of Internal Medicine II Cardiology, University of Ulm, Germany
    Arterioscler Thromb Vasc Biol 23:283-8. 2003
  7. ncbi Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products
    Nikolaus Marx
    Department of Internal Medicine II Cardiology, University of Ulm, Robert Koch Str 8, D 89081 Ulm, Germany
    Diabetes 53:2662-8. 2004
  8. ncbi [Peroxisome proliferator-activated receptors (PPARs) in the vessel wall: new regulators of gene expression in vascular cells]
    N Marx
    Abteilung Innere Medizin II Kardiologie Universität Ulm Robert Koch Str 8 89081 Ulm, Germany
    Z Kardiol 90:470-7. 2001
  9. ncbi Peroxisome proliferator-activated receptor gamma and atherosclerosis
    Nikolaus Marx
    Department of Internal Medicine II Cardiology, University of Ulm, Robert Koch Str 8, D 89081 Ulm, Germany
    Curr Hypertens Rep 4:71-7. 2002
  10. ncbi LXR activation inhibits chemokine-induced CD4-positive lymphocyte migration
    Daniel Walcher
    Department of Internal Medicine II Cardiology, University Ulm, Robert Koch Strasse 8, Ulm, Germany
    Basic Res Cardiol 105:487-94. 2010

Detail Information

Publications53

  1. ncbi C-peptide induces chemotaxis of human CD4-positive cells: involvement of pertussis toxin-sensitive G-proteins and phosphoinositide 3-kinase
    Daniel Walcher
    Department of Internal Medicine II-Cardiology, University of Ulm, Germany
    Diabetes 53:1664-70. 2004
    ..Thus, C-peptide might deposit in the arterial intima in diabetic patients during early atherogenesis and subsequently attract CD4(+) cells to migrate into the vessel wall...
  2. ncbi PPARalpha activators inhibit tissue factor expression and activity in human monocytes
    N Marx
    Department of Internal Medicine II Cardiology, University of Ulm, Germany
    Circulation 103:213-9. 2001
    ..Given that some of these substances reduce TF activity in patients, we tested whether PPARalpha activators limit TF responses in human monocytic cells...
  3. ncbi Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells
    Nikolaus Marx
    Department of Internal Medicine II Cardiology, University of Ulm, Robert Koch Str 8, D 89081 Ulm, Germany
    Circ Res 94:1168-78. 2004
    ..This review will focus on the role of PPARs in the vasculature and summarize the present understanding of their effects on atherogenesis and its cardiovascular complications...
  4. ncbi C-peptide colocalizes with macrophages in early arteriosclerotic lesions of diabetic subjects and induces monocyte chemotaxis in vitro
    Nikolaus Marx
    Department of Internal Medicine II Cardiology, University of Ulm, Robert Koch Str 8, D 89081 Ulm, Germany
    Arterioscler Thromb Vasc Biol 24:540-5. 2004
    ..This study tested the hypothesis that C-peptide might participate in atherogenesis in these patients...
  5. ncbi Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease
    Nikolaus Marx
    Department of Internal Medicine II Cardiology, University of Freiburg, Germany
    Circulation 107:1954-7. 2003
    ....
  6. ncbi Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease
    Nikolaus Marx
    Department of Internal Medicine II Cardiology, University of Ulm, Germany
    Arterioscler Thromb Vasc Biol 23:283-8. 2003
    ....
  7. ncbi Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products
    Nikolaus Marx
    Department of Internal Medicine II Cardiology, University of Ulm, Robert Koch Str 8, D 89081 Ulm, Germany
    Diabetes 53:2662-8. 2004
    ..These data provide new insight on how TZDs, in addition to their metabolic effects, might modulate the development of vascular dysfunction in diabetic patients...
  8. ncbi [Peroxisome proliferator-activated receptors (PPARs) in the vessel wall: new regulators of gene expression in vascular cells]
    N Marx
    Abteilung Innere Medizin II Kardiologie Universität Ulm Robert Koch Str 8 89081 Ulm, Germany
    Z Kardiol 90:470-7. 2001
    ..The following review will focus on these aspects of potential anti- or proatherogenic effects in the vessel wall and discuss potential clinical implications of these findings...
  9. ncbi Peroxisome proliferator-activated receptor gamma and atherosclerosis
    Nikolaus Marx
    Department of Internal Medicine II Cardiology, University of Ulm, Robert Koch Str 8, D 89081 Ulm, Germany
    Curr Hypertens Rep 4:71-7. 2002
    ..This review will focus on these aspects and discuss what PPARgamma activation in vascular cells could mean for atherogenesis and the development of atherosclerosis...
  10. ncbi LXR activation inhibits chemokine-induced CD4-positive lymphocyte migration
    Daniel Walcher
    Department of Internal Medicine II Cardiology, University Ulm, Robert Koch Strasse 8, Ulm, Germany
    Basic Res Cardiol 105:487-94. 2010
    ..Given the crucial importance of chemokine-induced T cell migration in early atherogenesis, LXR activators may be promising tools to modulate this effect...
  11. ncbi Rapid effect of single-dose rosiglitazone treatment on endothelial function in healthy men with normal glucose tolerance: data from a randomised, placebo-controlled, double-blind study
    Thomas Walcher
    Department of Internal Medicine II Cardiology, University of Ulm, Germany
    Diab Vasc Dis Res 7:178-85. 2010
    ....
  12. ncbi PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis
    Nikolaus Marx
    Department of Internal Medicine II, University of Ulm, Ulm, Germany
    Circ Res 90:703-10. 2002
    ....
  13. ncbi Resistin: a newly identified chemokine for human CD4-positive lymphocytes
    Daniel Walcher
    Department of Internal Medicine II Cardiology, University of Ulm, D 89081 Ulm, Germany
    Cardiovasc Res 85:167-74. 2010
    ..Therefore, the present study examined the effect of resistin on CD4-positive lymphocyte migration, an important process in early atherogenesis...
  14. ncbi C-Peptide induces vascular smooth muscle cell proliferation: involvement of SRC-kinase, phosphatidylinositol 3-kinase, and extracellular signal-regulated kinase 1/2
    Daniel Walcher
    Department of Internal Medicine II, Cardiology, University of Ulm, Germany
    Circ Res 99:1181-7. 2006
    ..These data suggest a novel mechanism how C-peptide may contribute to plaque development and restenosis formation in patients with insulin resistance and early type 2 diabetes mellitus...
  15. ncbi C-peptide promotes lesion development in a mouse model of arteriosclerosis
    Dusica Vasic
    Department of Internal Medicine II Cardiology, University of Ulm, Ulm, Germany
    J Cell Mol Med 16:927-35. 2012
    ..These data obtained in a mouse model of arteriosclerosis support the hypothesis that C-peptide may have an active role in atherogenesis in patients with diabetes and insulin resistance...
  16. ncbi Myocardial perfusion reserve in cardiovascular magnetic resonance: Correlation to coronary microvascular dysfunction
    Jochen Wohrle
    Department of Internal Medicine II, University of Ulm, Ulm, Germany
    J Cardiovasc Magn Reson 8:781-7. 2006
    ..CMR combined with adenosine could be proposed as a non-invasive tool to evaluate CMD...
  17. ncbi Impact of pioglitazone on coronary endothelial function in non-diabetic patients with coronary artery disease
    Jochen Wohrle
    Department of Internal Medicine II, University of Ulm, Ulm, Germany
    Clin Res Cardiol 97:726-33. 2008
    ..We studied the hypothesis that pioglitazone improves coronary endothelial dysfunction in non-diabetic patients with coronary artery disease (CAD) in a randomized, placebo-controlled, double-blind trial...
  18. ncbi Advanced glycation end products and C-peptide-modulators in diabetic vasculopathy and atherogenesis
    Daniel Walcher
    Department of Internal Medicine II Cardiology, University of Ulm, Robert Koch Str 8, 89081, Ulm, Germany
    Semin Immunopathol 31:103-11. 2009
    ....
  19. ncbi Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: data from a randomized placebo-controlled trial
    Franz Meisner
    Department of Thoracic and Vascular Surgery, University of Ulm, Germany
    Arterioscler Thromb Vasc Biol 26:845-50. 2006
    ..CONCLUSIONS: Four weeks of treatment with rosiglitazone significantly reduces vascular inflammation in nondiabetic patients, leading to a more stable type of arteriosclerotic lesion...
  20. ncbi T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance
    Ulrich Kintscher
    Department of Internal Medicine II Cardiology, University of Ulm, Robert Koch Str 8, D 89081 Ulm, Germany
    Arterioscler Thromb Vasc Biol 28:1304-10. 2008
    ..Adipose tissue inflammation may play a critical role in the pathogenesis of insulin resistance (IR). The present study examined the role of lymphocytes in adipose tissue inflammation and IR...
  21. ncbi Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers
    Jurgen Hetzel
    Department of Internal Medicine II Cardiology, University of Ulm, Ulm, Germany
    Arterioscler Thromb Vasc Biol 25:1804-9. 2005
    ..Therefore, the present study examined whether short-term rosiglitazone treatment influences endothelium-dependent vasodilation as well as serum levels of vascular disease biomarkers in healthy, nondiabetic subjects...
  22. ncbi Vascular effects of PPARgamma activators - from bench to bedside
    Nikolaus Marx
    Department of Internal Medicine II Cardiology, University of Ulm, Robert Koch Str 8, D 89081 Ulm, Germany
    Prog Lipid Res 46:283-96. 2007
    ..This review will focus on the vascular effects of PPARgamma activators and summarize the current knowledge of their modulatory function on atherogenesis and vascular disease...
  23. ncbi Insulin resistance and cardiovascular disease: the role of PPARgamma activators beyond their anti-diabetic action
    Daniel Walcher
    University of Ulm, Robert-Koch-Str. 8, D-89081 Ulm, Germany
    Diab Vasc Dis Res 1:76-81. 2004
    ....
  24. ncbi LXR activation reduces proinflammatory cytokine expression in human CD4-positive lymphocytes
    Daniel Walcher
    Department of Internal Medicine II, Cardiology, University of Ulm, Germany
    Arterioscler Thromb Vasc Biol 26:1022-8. 2006
    ..These data provide new insight how LXR activators might modulate the inflammatory process in atherogenesis and as such influence lesion development...
  25. ncbi Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients
    Nikolaus Marx
    Department of Internal Medicine II, Cardiology, University of Ulm, Ulm, Germany
    Circulation 112:2792-8. 2005
    ..These data bolster the hypothesis that antidiabetic thiazolidinediones, in addition to their metabolic effects, exhibit direct antirestenotic effects in the vasculature...
  26. ncbi Characterization of patients with acute chest pain using cardiac magnetic resonance imaging
    Vinzenz Hombach
    Department of Internal Medicine II, University of Ulm, Ulm, Germany
    Clin Res Cardiol 97:760-7. 2008
    ....
  27. ncbi Telmisartan inhibits CD4-positive lymphocyte migration independent of the angiotensin type 1 receptor via peroxisome proliferator-activated receptor-gamma
    Daniel Walcher
    Department of Internal Medicine II Cardiology, University of Ulm, Robert Koch Str 8, D 89081 Ulm, Germany
    Hypertension 51:259-66. 2008
    ..These data provide a novel mechanism to explain how telmisartan modulates lymphocyte activation by its PPARgamma-activating properties...
  28. ncbi Drinking modulates monocyte migration in healthy subjects: a randomised intervention study of water, ethanol, red wine and beer with or without alcohol
    Armin Imhof
    Department of Internal Medicine II, Cardiology, University of Ulm, Ulm, Medical Centre, Robert Koch Strasse 8, D 89081 Ulm, Germany
    Diab Vasc Dis Res 5:48-53. 2008
    ..Short-term intervention with moderate amounts of ethanol and de-alcoholised red wine inhibits monocyte migration ex vivo. This might represent one mechanism by which alcoholic beverages lower cardiovascular risk...
  29. ncbi In vivo study on the expression pattern of resistin in patients with abdominal aortic aneurysm
    Bernd M Muehling
    Department of Thoracic and Vascular Surgery, University of Ulm, Ulm, Germany
    Vasc Endovascular Surg 45:63-8. 2011
    ..To study the expression pattern of resistin in abdominal aortic aneurysms and to correlate its plasma levels to aneurysm size and statin therapy...
  30. ncbi C-Peptide and atherogenesis: C-Peptide as a mediator of lesion development in patients with type 2 diabetes mellitus?
    Nikolaus Marx
    Department of Internal Medicine II Cardiology, University of Ulm, Ulm 89073, Germany
    Exp Diabetes Res 2008:385108. 2008
    ..The following review will summarize the effects of C-peptide in vascular cells and discuss the potential role of C-peptide in atherogenesis in patients with type 2 diabetes...
  31. ncbi Cryorecanalization: a new approach for the immediate management of acute airway obstruction
    Martin Hetzel
    Department of Internal Medicine II Pulmonary Medicine, University Medical Center Ulm, Ulm, Germany
    J Thorac Cardiovasc Surg 127:1427-31. 2004
    ..In this study we demonstrate a newly developed cryoprobe allowing recanalization of tumor stenoses during a single intervention...
  32. ncbi Serum starvation and growth factor receptor expression in vascular smooth muscle cells
    Oliver Zimmermann
    Center for Cell and Gene Therapy, and Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Tex, USA
    J Vasc Res 43:157-65. 2006
    ..We hypothesized that serum starvation of SMCs may affect PDGFbeta-R and IGF-1-R expression and, consequently, the effect of their cognate ligands on SMC survival/proliferation...
  33. ncbi Inhibition of MMP-9 expression by PPARgamma activators in human bronchial epithelial cells
    M Hetzel
    Department of Internal Medicine II, University of Ulm, Robert Koch Strasse 8, D 89081 Ulm, Germany
    Thorax 58:778-83. 2003
    ..MMP-9 expression is induced by inflammatory mediators such as tumour necrosis factor (TNF)-alpha, but to date nothing is known about the mechanisms of inhibition of MMP-9 expression in these cells...
  34. ncbi Value of the proximal flow convergence method for quantification of the regurgitant volume in mitral regurgitation Influence of the mechanism of regurgitation, the imaging of the flow convergence region, and different calculation modalities
    G Grossmann
    Abteilung fur Kardiologie, Medizinische Klinik der Universität Ulm, Robert Koch Strasse 8, 89081 Ulm, Germany
    Z Kardiol 93:944-53. 2004
    ..Furthermore, the mode of imaging the flow convergence region and different correction algorithms for calculation of the regurgitant volume were compared...
  35. ncbi Pulmonary hemodynamics in obstructive sleep apnea: frequency and causes of pulmonary hypertension
    M Hetzel
    Department of Internal Medicine II, University Hospital, Ulm University, Germany
    Lung 181:157-66. 2003
    ..In conclusion, daytime PHT during exercise is frequently seen in patients with OSAS and normal lung function testing and is mainly caused by abnormally high PCWP, whereas PVR seems to play a minor role...
  36. ncbi C-peptide as a mediator of lesion development in early diabetes--a novel hypothesis
    Nikolaus Marx
    Department of Internal Medicine II Cardiology, University of Ulm, Germany
    Trends Cardiovasc Med 18:67-71. 2008
    ..The following review will summarize the effects of C-peptide in vascular cells and discuss the potential relevance of such C-peptide effects on atherogenesis in diabetic patients...
  37. ncbi Rosiglitazone and cardiovascular disease: a cardiologist's perspective
    Nikolaus Marx
    Department of Internal Medicine II, University of Ulm, Robert-Koch Strasse 8, D-89081 Ulm, Germany
    Diab Vasc Dis Res 4:80-1. 2007
  38. ncbi Effect of statin therapy on serum activity of proteinases and cytokines in patients with abdominal aortic aneurysm
    Bernd Muehling
    Department of Thoracic and Vascular Surgery, University of Ulm, Steinhovelstrasse 9, Ulm, Germany
    Vasc Health Risk Manag 4:1433-7. 2008
    ..Statins seem to exert an inhibitory effect on MMP activity in the aortic wall. No data exist on the effect of statins on serum activity of MMPs and inflammatory cytokines (interleukins, IL)...
  39. ncbi Dual stack black blood carotid artery CMR at 3T: application to wall thickness visualization
    Axel Bornstedt
    Department of Internal Medicine II Cardiology, University Hospital Ulm, Albert Einstein Allee 23, Ulm 89081, Germany
    J Cardiovasc Magn Reson 11:45. 2009
    ....
  40. ncbi Complement and dilated cardiomyopathy: a role of sublytic terminal complement complex-induced tumor necrosis factor-alpha synthesis in cardiac myocytes
    Thomas P Zwaka
    Department of Internal Medicine II Cardiology, University of Ulm, Ulm, Germany
    Am J Pathol 161:449-57. 2002
    ..We conclude that chronic immunoglobulin-mediated complement activation in the myocardium may contribute in part to the progression of dilated cardiomyopathy via C5b-9-induced TNF-alpha expression in cardiac myocytes...
  41. ncbi C-Peptide in the vessel wall
    Daniel Walcher
    Department of Internal Medicine II, Cardiology, University of Ulm, Germany
    Rev Diabet Stud 6:180-6. 2009
    ..The present review summarizes this new pathophysiological aspect and discusses the potential relevance for lesion development...
  42. ncbi PPARgamma and vascular inflammation: adding another piece to the puzzle
    Nikolaus Marx
    Circ Res 91:373-4. 2002
  43. ncbi Focussed section "Effect of oral antidiabetic drugs on micro- and macrovascular complications in patients with diabetes mellitus--update 2008"
    Nikolaus Marx
    Cardiovasc Drugs Ther 22:205-6. 2008
  44. ncbi Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk--the PIOSTAT Study
    Thomas Forst
    Institute for Clinical Research and Development, Medical Department, D 55116 Mainz, Germany
    Metabolism 56:491-6. 2007
    ..05) during PIO/SIM treatment. Lipid parameters improved during SIM treatment but not during PIO treatment. Combined treatment with PIO/SIM was superior in improving overall cardiovascular risk profile than every single drug...
  45. ncbi PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties
    M Amine Bouhlel
    Institut Pasteur de Lille, F 59019 Lille, France INSERM, U545, F 59019 Lille, France
    Cell Metab 6:137-43. 2007
    ..These data demonstrate that PPARgamma activation skews human monocytes toward an anti-inflammatory M2 phenotype...
  46. ncbi Endothelial dysfunction and cardiovascular disease--the lull before the storm
    Nikolaus Marx
    Diab Vasc Dis Res 4:82-3. 2007
  47. ncbi Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study
    Andreas Pfutzner
    IKFE Institute for Clinical Research and Development, Parcusstrasse 8, D 55116 Mainz, Germany
    J Am Coll Cardiol 45:1925-31. 2005
    ..This study was performed to assess whether the anti-inflammatory and antiatherogenic effects of pioglitazone suggested by animal experiments are reproducible in man and independent from improvements in metabolic control...
  48. ncbi Tranilast inhibits cytokine-induced nuclear factor kappaB activation in vascular endothelial cells
    Martin Spiecker
    Department of Medicine II, University of Bochum, Bochum, Germany
    Mol Pharmacol 62:856-63. 2002
    ..We propose that inhibition of NF-kappaB dependent gene transcription contributes to the anti-inflammatory effects of tranilast...
  49. ncbi Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study
    Markolf Hanefeld
    GWT, Center for Clinical Studies, Dresden, Germany
    J Am Coll Cardiol 49:290-7. 2007
    ....
  50. ncbi Inter-subject differences in constitutive expression levels of the clock gene in man
    Anthony J Balmforth
    Diabetes and Cardiovascular Research in Leeds, Faculty of Medicine and Health, University of Leeds, Leeds, UK
    Diab Vasc Dis Res 4:39-43. 2007
    ..They could influence susceptibility to disruption of normal circadian rhythms, which occur in pathophysiological conditions pertaining to diabetes and cardiovascular disease...
  51. ncbi Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice
    Erwin Blessing
    Medizinische Klinik III, Universitat Heidelberg, Heidelberg, Germany
    Atherosclerosis 199:295-303. 2008
    ....
  52. ncbi Diabetes and acute coronary syndromes--a cardiologist's view
    Nikolaus Marx
    Diab Vasc Dis Res 2:101-2. 2005
  53. ncbi Induction of CXCR2 receptor by peroxisome proliferator-activated receptor gamma in human macrophages
    Elena Rigamonti
    Institut Pasteur de Lille, France
    Arterioscler Thromb Vasc Biol 28:932-9. 2008
    ..In this study, we investigated whether PPAR-gamma also plays a role in the regulation of the CXC chemokine pathway...